- Home
- ACHC vs EYPT Comparison
ACHC vs EYPT Comparison
Compare ACHC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | EYPT |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | 214 |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2011 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ACHC | EYPT |
|---|---|---|
| Price | $23.99 | $13.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $21.64 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 3.3M | 1.2M |
| Earning Date | 05-11-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,312,769,000.00 | $7,539,000.00 |
| Revenue This Year | $5.08 | N/A |
| Revenue Next Year | $5.98 | $1,031.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.04 | N/A |
| 52 Week Low | $11.43 | $3.91 |
| 52 Week High | $31.04 | $19.11 |
Technical Indicators
Market Signals| Indicator | ACHC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 39.10 |
| Support Level | $23.02 | $12.47 |
| Resistance Level | $25.07 | $13.32 |
| Average True Range (ATR) | 1.20 | 0.84 |
| MACD | -0.38 | -0.28 |
| Stochastic Oscillator | 59.90 | 22.70 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.